Development of Celecoxib Granules for Manufacturing of Prolonged Release Celecoxib Capsules and Tablets
https://doi.org/10.33380/2305-2066-2022-11-1-68-73
Abstract
Introduction. To reduce frequency of taking celecoxib dosage forms, as a highly effective drugs of the latest generation for the treatment of inflammatory diseases of the musculoskeletal system, it is advisable to develop pharmaceutical dosage form with modified release, which will reduce side effects and costs treatment.
Aim. The purpose of this study was to develop formulations of prolonged release celecoxib granules.
Materials and methods. Experiments were carried out with materials and equipments of the scientific laboratories of the company LEM pharma (Hama, Syria). The physico-chemical and technological properties of the experimental samples of granules and tablets of celecoxib were determined according to the methods of the American Pharmacopoeia USP 41 NF 36 edition.
Results and discussion. The choice of excipients, in particular, cellulosic polymers to control releasing celecoxib was carried out. The compositions of six model samples of celecoxib granules were proposed. The technological characteristics of the samples of granules (index Hausner, Carr ratio, Particle size distribution and moisture content) have been determined, using a dissolution test, their suitability for obtaining capsules and matrix tablets of prolonged release has been established.
Conclusion. The compositions of granules celecoxib with modified release are developed, which can be used to obtain capsules, as well as matrix tablets as the final pharmaceutical form.
About the Authors
A. Alkhodri
Peoples Friendship University of Russia (RUDN University),
6, Mikluho-Maklaya str., Moscow, 117198
Russian Federation
Russian Federation
LEM pharma, Medical company,
Hama, Syria
Ahmed Alkhodri
S. N. Suslina
Peoples Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
6, Mikluho-Maklaya str., Moscow, 117198, Russia
References
1. Demina N. B. Modern Trends in Development of the Technology of Matrix Drug Dosage Forms with Modified Release. Pharmaceutical Chemistry Journal. 2016;50(7):44–50. DOI: 10.30906/0023-1134-2016-50-7-44-50. (In Russ.)
2. World health organization (WHO). Musculoskeletal conditions. Available at: https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions. Accessed: 08.02.2021.
3. Hootman J. M., Helmick C. G., Barbour K. E., Theis K. A., Boring M. A. Updated projected prevalence of self‐reported doctor‐diagnosed arthritis and arthritis‐attributable activity limitation among US adults, 2015–2040. Arthritis & Rheumatology. 2016;68(7):1582–1587. DOI: 10.1002/art.39692.
4. Samartsev I. N., Zhivolupov S. A., Nazhmudinov R. Z. Identification of non-steroidal anti-inflammatory drugs as a necessity basis of effectiveness and risk correlation conception. Zhurnal nevrologii i psikhiatrii im. CC Korsakova. 2019;119(12):124–131. (In Russ.) DOI: 10.17116/jnevro2019119121124.
5. Meng F., Ferreira R., Zhang F. Effect of surfactant level on properties of celecoxib amorphous solid dispersions. Journal of Drug Delivery Science and Technology. 2019;49:301–307. DOI: 10.1016/j.jddst.2018.11.026
6. CELECOXIB COMPOSITIONS – Patent Pfizer company in USA No. RE44048. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=793. Accessed: 04.03.2013.
7. CELECOXIB COMPOSITIONS – European Patent Office – EP 1049467 B1. Available at: https://patentimages.storage.googleapis.com/1f/12/8b/0d155cbe051c78/EP1049467B1.pdf. Accessed: 09.10.2002.
8. Grigor’yeva M. V. Polymer systems with controlled release of bioactive compounds. Biotechnologia. 2011;4(2):9–23. (In Russ.)
9. Salve P., Aherrao S., Bali N. Development and Evaluation of Sustained Release Dosage Form using Hydrophilic and Hydrophobic Materials. Research Journal of Pharmacy and Technology. 2016;9(5):481–489. DOI: 10.5958/0974-360X.2016.00089.5.
10. Qi X., Chen H., Rui Y., Yang F., Ma N., Wu Z. Floating tablets for controlled release of ofloxacin via compression coating of hydroxypropyl cellulose combined with effervescent agent. International journal of pharmaceutics. 2015;489(1–2):210–217. DOI: 10.1016/j.ijpharm.2015.05.007.
11. Abdulhameed K. A. A., Salih N. A. Controlled Release of Cefixime using Sodium Carboxymethyl Cellulose Polymer. Research Journal of Pharmacy and Technology. 2019;12(9):4073–4079. DOI: 10.5958/0974-360X.2019.00701.7.
12. Zhang F., Meng F., Wang Z. Y., Na W. Interpolymer complexation between copovidone and carbopol and its effect on drug release from matrix tablets. Drug development and industrial pharmacy. 2017;43(2):190–203. DOI: 10.1080/03639045.2016.1230625.
13. USP 41 – NF 36 (2018) The United States Pharmacopeial Convention, USA. Available at: https://www.uspnf.com/notices/usp-41-nf-36-online-table-contents-admissions. Accessed: 04.03.2013.
14. Fonteyne M., Soares S., Vercruysse J., Peeters E., Burggraeve A., Vervaet C., De Beer T. Prediction of quality attributes of continuously produced granules using complementary pat tools. European journal of pharmaceutics and biopharmaceutics. 2012;82(2):429–436. DOI: 10.1016/j.ejpb.2012.07.017.
15. Thapa P., Lee A. R., Choi D. H., Jeong S. H. Effects of moisture content and compression pressure of various deforming granules on the physical properties of tablets. Powder technology. 2017;310:92–102. DOI: 10.1016/j.powtec.2017.01.021.
16. Fitriani L., Abdillah R., Ben E. S. Formulation of Metformin HCl Floating Tablet using HPC, HPMC K100M, and the Combinations. Jurnal Sains Farmasi & Klinis. 2017;4(1):79–82. DOI: 10.29208/jsfk.2017.4.1.201.
Supplementary files
|
|
1. Графический абстракт | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(888KB)
|
Indexing metadata ▾ | |
Review
For citations:
Alkhodri A., Suslina S.N. Development of Celecoxib Granules for Manufacturing of Prolonged Release Celecoxib Capsules and Tablets. Drug development & registration. 2022;11(1):68-73. (In Russ.) https://doi.org/10.33380/2305-2066-2022-11-1-68-73
Views:
1478
Email this article 